In our commitment to R&D, the numbers speak for themselves
We follow the science where we can make the greatest difference
March 7, 2024
Our scientists are revolutionizing how we discover and develop medicines and vaccines to address unmet medical needs, focused on innovating in oncology, vaccines, infectious diseases, cardio-metabolic disorders, immunology and neuroscience.
With a science-led but portfolio-driven approach to our pipeline, we’re harnessing new technologies to accelerate the drug discovery process as we use the power of leading-edge science to save and improve the lives of humans and animals around the world. And, we’re continuing to invest in research and discovery efforts, like breaking new ground in London and uniting research and manufacturing to help patients faster in Ireland.
Here’s a look at how we got there:
2023 by the numbers
$30.5 billion
Our research and development investment
21,800
Employees driving our research activities
1,400+
Publications by our scientists in peer-reviewed journals
100,000+
Patients enrolled in our clinical trials at more than 21,000+ sites worldwide
50+
Countries around the world where we are conducting clinical trials
330+
Late-stage clinical trials around the world
2
New major acquisitions to broaden our reach
We’re dedicated to translating breakthrough research into life-changing medicines and vaccines.
Are you interested in a career in R&D? Join us to help address some of the world's most difficult challenges.
